Tag Archives: 21st Century Cures Act
With the nomination of Dr. Scott Gottlieb to head the FDA headed to the Senate floor, we can expect another Goldilocks debate about whether today’s FDA is too lenient, too tough, or just right in reviewing new prescription drugs.
May 1, 2017
A total of 12.2 million people selected or were automatically enrolled in marketplace plans during the 2017 ACA open enrollment period, reflecting a late-January enrollment slowdown. And the IRS temporarily waived employer penalties connected with a notice about a new health care financing vehicle.
March 16, 2017
Revisiting how the public health community established the systems needed to US AIDS mortality rate in half can serve as a useful guide for states and policymakers to set up the most effective response to the current crisis.
March 13, 2017
Central to the PMI is the All of Us Research Program, which aims to enroll 1 million or more volunteers throughout the United States. If successful, it would be one of the largest longitudinal cohorts ever developed in this country.
February 28, 2017
While it is difficult to ignore the positive aspects of the 21st Century Cures Act, there is also legitimate cause for concern that the traditional regulatory standards we have come to rely on may be modified, with unknown long-term effects on the safety and efficacy of new drugs and devices.
February 14, 2017
Cures Act, FDA Draft Guidance Suggest Flexibility On Communication Of Real-World Drug Impacts, Though Questions Remain
A key question pertains to the “real-world” impacts of prescription drugs, such as their potential to improve adherence, prevent hospitalizations, and reduce health costs.
February 2, 2017
Tremendous uncertainty awaits, though I expect that we will see a slowing down of the repeal and replace process, with even the individual mandate persisting for some time; unmaking the Affordable Care Act without leaving millions stranded will be harder than the campaign may have suggested.
January 5, 2017
We believe the bill’s potential benefits and modestly enhanced funding for scientific advancement are far outweighed by the increased risk of patient harm, and added pressure on the FDA to rush new products to market without adequate evidence.
November 30, 2016
Congress is set to adjourn for an extended election-year summer recess on July 15, and time is running out to pass the 21st Century Cures Act. That’s a good thing, because the legislation, while containing some useful measures, is flawed, and Congress should postpone consideration until 2017.
July 11, 2016
The role of patients in health research is changing dramatically to play a meaningful role in research. That’s critical, because health care is increasingly judged on the value it delivers to patients, as well as clinicians and the nation as a whole.
May 19, 2016